Variables impacting effectiveness of competitive P-gp antagonists
P-gp prognostic power in study population |
| Frequency MDR1 phenotype |
| Functional P-gp |
| Effective modulator blood concentration |
| Duration of modulator and anticancer drug (ACD) exposure |
| ACD substrate avidity for P-gp |
| Overlapping pharmacophore interaction (ACD vs modulator) |
| Change in ACD elimination |
| Non—P-gp mechanisms of resistance |
P-gp prognostic power in study population |
| Frequency MDR1 phenotype |
| Functional P-gp |
| Effective modulator blood concentration |
| Duration of modulator and anticancer drug (ACD) exposure |
| ACD substrate avidity for P-gp |
| Overlapping pharmacophore interaction (ACD vs modulator) |
| Change in ACD elimination |
| Non—P-gp mechanisms of resistance |